Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.

摘要: Nitroglycerin (NTG), a drug that has been in clinical use for more than century, range of actions which make it particular interest an oncological setting. It is generally accepted the main mechanism action NTG via production nitric oxide (NO), improves cardiac oxygenation multiple mechanisms including improved blood flow (vasodilation), decreased platelet aggregation, increased erythrocyte O2 release and mitochondrial utilization oxygen. Its vasoactive properties mean potential to exploit fully enhanced permeability retention effect delivering anti-cancer drugs tumour tissues. Moreover can reduce HIF-1α levels hypoxic tissues this may have anti-angiogenic, pro-apoptotic anti-efflux effects. Additionally enhance anti-tumour immunity. Pre-clinical data on these are summarised discussed. While there evidence positive as monotherapy prostate cancer, mixed results NSCLC where initially yet be replicated. Based presented, case made further exploration benefits accrue cancer patients warranted. Additionally, proposed synergise with number other drugs, repurposed discussed supplementary material appended paper.